-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guillain-Barré syndrome is an immune- mediated multiple radiculopathy, which affects 0.
Immunization is usually a unipolar disease, which progresses rapidly, limbs are weak, and its clinical severity, course and prognosis vary.
In patients with severe Guillain-Barré syndrome, a standard dose (2 g/kg) of intravenous immunoglobulin therapy is not enough.
infection
In this randomized, double-blind, placebo-controlled trial (SID-GBS), this study included patients with Guillain-Barré syndrome (≥12 years old) admitted to a Dutch hospital.
Between February 16, 2010 and June 5, 2018, 327 of 339 patients were included in the evaluation, and 112 of them had a poor prognosis.
thrombus
In summary, for patients with Guillain-Barré syndrome with poor prognosis, the study found that there is no obvious clinical benefit for a second intravenous immunoglobulin therapy shortly after the first standard intravenous immunoglobulin dose.
There is no obvious clinical benefit for a second intravenous immunoglobulin treatment shortly after the first standard intravenous immunoglobulin dose.
Walgaard, ChristaWalgaard, Christa et al.
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
The Lancet Neurology, Volume 20, Issue 4, 275-283 Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
Leave a message here
